Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells 64,533 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFLGet Free Report) insider Campbell Rogers sold 64,533 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.64, for a total transaction of $1,590,093.12. Following the sale, the insider directly owned 81,002 shares of the company’s stock, valued at approximately $1,995,889.28. This trade represents a 44.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

  • On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $25.69, for a total transaction of $1,657,852.77.
  • On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97.

Heartflow Price Performance

Shares of Heartflow stock remained flat at $24.83 during trading hours on Friday. 1,818,146 shares of the stock traded hands, compared to its average volume of 1,704,032. The firm has a fifty day moving average price of $25.12 and a two-hundred day moving average price of $29.90. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $41.22. The firm has a market cap of $2.13 billion and a P/E ratio of -12.48.

Hedge Funds Weigh In On Heartflow

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Heartflow during the fourth quarter valued at about $27,000. TFC Financial Management Inc. acquired a new position in shares of Heartflow in the third quarter worth about $40,000. Russell Investments Group Ltd. purchased a new position in Heartflow in the fourth quarter valued at about $45,000. Legal & General Group Plc acquired a new stake in Heartflow during the 3rd quarter valued at approximately $59,000. Finally, Strs Ohio purchased a new stake in Heartflow during the 4th quarter worth approximately $99,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HTFL shares. JPMorgan Chase & Co. cut their price objective on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Canaccord Genuity Group upped their target price on Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Wells Fargo & Company dropped their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

View Our Latest Research Report on Heartflow

About Heartflow

(Get Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

Featured Stories

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.